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Summary The methylation of the human oestrogen receptor (ER) gene was analysed by restriction enzymes
in normal and neoplastic human breast tissues and cell lines. CCGG sequences in regions inside the gene,
which are methylated both in normal breast and in tissues that are not the target of the oestrogen, are
hypomethylated in 30% of tumours, both ER + and ER - carcinomas. Moreover, 5' sequences of the gene,
which are hypomethylated in normal breast and not in tissues not the target of oestrogen, are methylated to a
lower degree in ER + carcinomas, whereas they are methylated to a greater degree in ER - carcinomas.
However, the same region is equally hypomethylated in both ER + and ER - cancer cell lines. Our results
indicate that in breast carcinomas ER DNA methylation is deranged, and in cancer cell lines is different from
that observed in primary tumours. Furthermore, the abnormal methylation in the 5' end seems to be related to
abnormal expression, namely diffuse hypomethylation in carcinomas with high ER content and hypermethyla-
tion in carcinomas without ER. These findings support our previous hypothesis that DNA methylation could
be involved in the control of ER gene expression and demonstrate that abnormal ER gene methylation is a
typical feature of breast cancers.
Several experimental and clinical data have established that
oestrogen plays a major role in breast development and
neoplasia (Henderson et al., 1988; Dickson & Lipman, 1987),
and that there is a relationship between the abnormal expres-
sion of the oestrogen receptor (ER) and the growth of trans-
formed mammary cells (Henderson et al., 1988; Dickson &
Lipman, 1987; De Sombre et al., 1979; Perrotteau et al.,
1987).
Recent evidence suggests that DNA methylation, which
occurs in the cytosine of CpG doublets (Razin et al., 1984), is
important in multilevel mechanisms regulating gene expres-
sion and differentiation in eukaryotes (Razin & Szyf, 1984;
Jaenisch & Jahner, 1984). Although there are some dis-
crepant reports in the literature, inverse correlation exists
between methylation and expression of several normal genes
(Doerfler, 1983). In addition, it is suggested that DNA
methylation is deranged in cancer cells (Jones, 1986; Goelz et
al., 1985), and possibly contributes to the aberrant gene
expression observed in cancer (Boehm et al., 1983). As
methylation of the ER gene may be one of the molecular
mechanisms involved in the control of ER gene expression,
changes in ER DNA methylation may be relevant in the
abnormal expression of this gene and therefore for neoplastic
growth and/or tumour promotion of oestrogen target cells.
We have recently reported an inverse correlation between
the extent of methylation and the expression of the ER gene
in normal human tissues (Piva et al., 1989a). The 5' region of
the gene is demethylated in normal endometrium, which
contains high ER levels, and strongly methylated in white
blood cells, which do not contain ER. In addition, a DNA
region, internal to the gene and usually methylated in normal
endometrium, is consistently hypomethylated in endometrial
carcinomas, in association with a fall of ER gene expression
(Piva et al., 1989b). However, it is unclear whether the
decrease in expression of the ER gene is related to the
abnormal hypomethylation or whether this hypomethylation
is an invariable property of specific tumours.
Both points could also be relevant for breast cancers.
Primary breast carcinomas are known to be heterogeneous
with respect to the ER protein and ER mRNA content
(Henry et al., 1988), and ER + and ER - breast cancer cell
lines are available. In addition, it has been suggested that
changes in DNA methylation are involved in steroid-induced
gene activation, thus possibly inducing progression of breast
tumours from the steroid-sensitive to the steroid-insensitive
state (Darbre & King, 1984).
We report here the methylation and the expression of ER
DNA in normal breast, and in carcinomas breast tissues and
cell lines with different content of ER.
Materials and methods
Patients
Twenty cases of primary breast cancers diagnosed as ductal
carcinoma (not otherwise specified) were used in the present
study. The age of the patients varied from 40 to 80 years
(mean 57 years). Four patients were premenopausal and 16
post-menopausal. In addition, five cases of fibroadenomas
were included, aged from 20 to 45 years.
Tissue samples were frozen immediately after surgery and
processed for diagnostic procedures and ER status evalu-
ations. Normal breast samples from the same patients (in 11
cases) were removed from an area far from the tumour and
checked in frozen sections. Only tumour samples with less
than 10% of stromal tissues were analysed for DNA
methylation. Tissues and their metastatic lymphonodes were
stored at - 70°C until assay. Blood samples were obtained
from the same patients.
ER assays
Sections from frozen tissues were assayed immuno-
cytochemically for ER using the ER-ICA Monoclonal kit
(Abbot), as previously described (Goussard et al., 1985; Di
Fronzo et al., 1986; Pertschuk et al., 1985). In all cases the
ER status was also determined biochemically using the
dextran-coated charcol assay (DCC). Staining intensity of
target cells nuclei was subjectively graded and recorded as
low (+), intermediate (+ +) and high (+ + +) or negative
(-), and averaged for each observed area.
Cell culture
Breast cancer cell lines were MCF7, T47D (both ER +) and
MDA-MB-231 (ER -). Cells were grown in a-MEM medium
for 4 days, in 5% CO2 humidified atmosphere, as already
described (Piva et al., 1988).
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RNA isolation and analysis
Frozen specimens were pulverised with a microdismembrator.
Powdered material was used for cytoplasmic and nuclei
preparation, according to the method described by White
and Bancroft (1982). RNA was prepared from cytoplasm by
phenol-chloroform extraction and analysed by Northern blot.
TenILg RNA was formaldehyde denatured, electrophoresed
in denaturating agarose gel (2.2 M formaldehyde) and blotted
to Gene Screen Plus filters (NEN) (Piva et al., 1988).
DNA isolation and analysis
DNA was obtained from nuclei by proteinase K treatment
and phenol-chloroform extraction (Maniatis et al., 1982).
Tenjig DNA was digested with an excess of HpaII and MspI
restriction enzymes respectively or with enzymes not sensitive
to methylation (5-10 units ig-' DNA) in a total reaction
mixture of 250ftl, under the conditions recommended by the
suppliers. To check that enzymatic digestion was complete, a
15 ,Al aliquot was withdrawn from the reaction mixture and
1 ul of bacterial phage lambda DNA (0.5fig) was added.
After incubation with the reaction mixture, the phage lambda
and human DNA samples were analysed by agarose gel
electrophoresis to ensure that digestion of lambda DNA was
complete. After digestion and EtOH precipitation, DNA
fragments were separated on 0.8% agarose gel, stained with
ethidium bromide and photographed through a UV trans-
illuminator (Maniatis et al., 1982).
RNA and DNA hybridisation
Nucleic acids were immobilised on the filters which were
hybridised in formamide at 42°C as described by the Gene
Screen manual of NEN. After hybridisation, filters were
washed and treated as previously described (Piva et al.,
1989b). The ER DNA probes utilised in our study were the
pOR3 (Green et al., 1986) and pGHERl (Piva et al., 1989b)
(see Figures 2 and 3), a cDNA and a genomic 5' end
sequence respectively, which cover most of the codifying
parts of ER gene. The probes were 32P-labelled by nick
translation or by a multiprime system (Amersham).
Results
Expression ofER gene in human breast carcinomas
The expression of ER in the tumour tissues was studied by
immunocytochemical analysis of tissue sections and by
measuring ER mRNA by Northern blot hybridisation, as
shown in Table I and in Figure 1.
According to the criteria for grading ER immunostaining,
15 cases were positive (ER +) and five negative (ER -) out
of the 20 cases analysed (see Table I). Positive immunostain-
ing was localised in the nucleus. Heterogeneity was common
with respect to both the intensity of immunostaining and the
percentage of immunostained nuclei, thus reflecting
heterogeneity of tumour cell populations.
ER mRNA of 6.7 kb was detected in cancer specimens
with ER and in control ER + MCF7 and T47D cell lines, as
shown in Figure 1. This RNA band was not detectable in the
MDA-MB231 ER - cell line, and in ER - tumour samples
Table I ER content in 20 breast cancers and five fibroadenomas
Breast ER status Menopausal
tumours - + ++ +++ status
Ductal carcinomas (20) 2 1 0 1 Pre
3 4 6 3 Post
Fibroadenomas (5) 0 5 0 0 Pre
Cancers were all of ductal type. ER status has been evaluated by
ER-ICA monoclonal kit, as described in the Materials and methods
section.
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Figure 1 Northern blot analysis of cytoplasmic RNA from
ER- and ER + breast carcinoma tissues and cell lines. Total
RNA was denatured in formamide, electrophoresed in 1.1%
agarose gel and transferred to a filter, as described in Materials
and methods. The filter was hybridised to 32P-labelled pOR3
cDNA probe. The size of ER mRNA of 6.7 kb was determined
on the basis of ribosomal RNA markers (28 and 18S). C1 and
C2, ER - carcinomas; C3, C4 and C5, ER + carcinomas. MDA
(ER -), T47D (ER +) and MCF7 (ER +): cancer cell lines.
(Figure 1). Abnormal ER mRNA bands were not observed
in the 14 cancer samples investigated for ER RNA content,
and all the 10 samples containing ER mRNA were positive
to ER antibody.
Restriction enzyme mapping ofER gene in breast carcinomas
Before analysing methylation of ER gene, we examined DNA
samples by Southern blotting technique after digestion with
four different restriction enzymes (PvuII, BamHI, Hind III,
TaqI) and hybridisation to a cDNA and 5' genomic probes
(shown in Figures 2 and 3). The pattern of DNA digests was
identical in the 11 normal and 20 neoplastic breast samples
(data not shown). The only differences were observed in
PvuII patterns, but they were caused by a PvuII poly-
morphism (RFLP) (Castagnoli et al., 1987).
Methylation inside the ER gene in human breast carcinomas
For methylation analysis, the methylation-sensitive restriction
endonuclease HpaII was used. This enzyme cuts CCGG sites,
but does not function if the internal cytosine is methylated.
The enzyme MspI provides a control for HpaII, since it
cleaves CCGG regardless of the methylation state of the
internal cytosine (Maniatis et al., 1982). The results of MspI/
HpaII analysis of ER gene in breast tissues after hybridisa-
tion to the pOR3 cDNA probe are shown in Figure 2.
MspI digestion of the DNA from a normal breast sample
(n) and from its carcinomatous counterpart (c) gave rise to
four ER specific fragments (11, 5.8, 3.5 and 1.6kb long),
which were identical in all the other normal and neoplastic
tissues examined (data not presented).
HpaII digestion of DNA from normal breast tissue (nl)
gave rise to high molecular weight fragments, indicating
methylation of CCGG sites located in the gene regions which
are hybridised by the cDNA probe. Large DNA bands were
found also in white blood cell DNA (wbc) and in metastatic
lymphonodes (ml) of the same subject, indicating that these
CCGG sites were also methylated in tissues which are not
targets of oestrogens.
A similar digestion pattern was observed in the ER+
carcinoma of the same patient (cI), in the c2 ER + and c4
ER- carcinomas. The same result was also obtained in the
11 normal samples, in the five fibroadenomas and in 14 of
the 20 breast carcinomas examined (data not presented).
In the other six carcinomas and in the cell lines examined,
in addition to high molecular weight fragments, variable
bands ranging from 10 to 3.2 kb in size were observed (see c3
ER +, c5 ER - and MCF7 and MDA of Figure 2), pro-
duced by hypomethylation of some intragenic CCGG sites.
These cell lines were either positive or negative to the ER
antibody.
The pattern of hypomethylated carcinomas and cell lines
was similar to that observed in normal (en), but not in
carcinomatous (ec) endometrium, which constantly showed272 R. PIVA et al.
pOR3
.0 '1' N qt n a 3:' C0 o o o
u ac
UWUJ WUJ
_ 11
-a-6
- 3.5
_ 1.6
Hpall MSpl lHpall
6.3 kb
pOR3
Figure 2 Southern blot hybridisation of DNA from human normal (n) and neoplastic (c) breast tissues and cell lines (MDA,
MCF7). In case 1 white blood cells (wbc) and metastatic lymphonodes (ml) are included. On the right side of the figure normal
(En) and carcinomatous (Ec) endometrium are included. Samples of 10 fig of DNA were digested with either HpaII or MspI and
hybridised with 32P-labelled pOR3 cDNA probe. See Materials and methods for technical details. c-1, c-2 and c-3: ER +
carcinomas (+ + +,+, + + ER status respectively). c-4 and c-5: ER - carcinomas. In the lower part of the figure the ER cDNA is
reported with the MspI/HpaII sites (o) and PvuIl site (P). The pOR3 probe is also shown.
the 1.6 kb fragment indicating a lower degree of methylation.
Taken together the results indicate that some CCGG sites
located inside the ER gene are rarely hypomethylated in
breast carcinomas, but always in breast cell lines,
independently of their ER content.
The lack of the restriction map of MspI/HpaII sites in the
inner regions of the gene precludes the identification of sites
which can be undermethylated. On the other hand, we have
recently mapped the HpaII/MspI sites in the 5' region of the
gene (Piva et al., 1989a), making it easier to estimate
methylation accurately in neoplastic tissues.
Methylation ofthe 5' end ofthe ER gene
Figure 3a shows the map of the BamHI and MspI/HpaII
restriction sites at the 5' end of the ER gene and the ER 5'
genomic probe (pGHERl) with the B and A sub-fragments.
After hybridisation of BamHI digested DNA with this
probe (Figure 3b), two bands of 2.5 and 4.7 kb appeared;
they were positive to the B and A sub-fragments respectively
(data not presented), and were generated by cleavage of B1,
B2 and B3 sites, as shown in the map of Figure 3a and by
Piva et al. (1989a).
After HpaII treatment of BamHI digested DNA from
white blood cells (wbc), the BamHI bands of 4.7 and 2.5 kb
disappeared, and three smaller fragments, 3.2, 2.8, 2.4 kb in
size, were detected (Figure 3b). Both the 3.2 and 2.8 kb
fragments originated from the 4.7 kb band by cleavage of B3
and demethylated Ml and Ml13 sites respectively. The co-
existence of 3.2 and 2.8 kb bands indicated that M13 was
methylated in some cells and not in others and it was refer-
red to as a 'partially methylated site'. The 2.4 kb band
originated from the 2.5 by Bl and demethylated M2 sites.
Fragments smaller than 0.6 kb originating from demethylated
HpaII/MspI sites located between M2 and MIO were not
always transferred efficiently to the filter, and were not
clearly evident in the blot (Piva et al., 1989a). These sites
were found to be demethylated in all tissues, irrespective of
the expression of the ER protein (data not shown).
In normal breast DNA (n), the 3.2 kb band was very faint
and a new band of 1.6 kb was detectable, originating from
cleavage of the demethylated Ml and M2 CCGG sites. Thus
the Ml and Ml13 sites were less methylated in breast than in
white blood cells, where the ER protein is absent, suggesting
the existence of tissue-specific methylation related to the
switch-off of the gene. The HpaII/BamHI pattern of the
normal breast samples was similar to that observed in the
other normal and adenomatous breast samples examined
(data not presented).
In contrast, heterogeneous methylation patterns were
found in HpaII/BamHI digests of breast carcinomas and cell
lines. In ER + cancers (cl and c2) the 2.8 and 2.4 kb bands
were either less marked than in normal tissue (n) or unde-
tectable; the 1.6 kb band increased in intensity, and a new
fragment of 0.7 kb appeared on the blot. This last fragment
originated from the M13 and M14 demethylated sites. This
result implies a loss of methylation in the 5' region of the ER
gene in these two carcinomas, although they showed a
methylated pattern inside the gene (cl blots of Figures 2 and
3 were the same). A similar methylation pattern was observed
in 13 of the 15 ER + carcinomas.
In ER - cancers (c3 and c4) the 3.2 kb band was evident
and the 2.4 was more marked than in normal tissue, while
the 0.7 and 1.6 kb bands were fainter or absent, indicating
the methylation of M13, M14 and Ml sites. These methyla-
tion patterns were similar to those observed in metastatic
lymphonodes (ml 3) and white blood cells (wbc 3 and 4),
which are not known to express the ER gene. In addition,
they were observed in four of the five ER - carcinomas.
In both ER - and ER + carcinoma cell lines (MDA,
MCF7 and T47D of Figure 3) intense 1.6 and 0.7 kb bands
were present. A similar pattern was found in carcinomatous
and normal endometrium (en and ec) which always showed
the lowest degree of methylation of the ER gene.
These results indicate that Ml, M13 and M14 CCGG sites
were hypomethylated in the majority of ER + carcinomas
and demethylated in cell lines, whereas they were methylated
in the majority of ER - carcinomas.
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Figure 3 Different methylation extent of Hpall/MspI sites (M) in the 5' sequence of the ER gene in breast carcinomas and cell
lines. a, Map of the BamHI (B) and MspI/HpaII (M) sites in the 5' genomic region of the human ER gene. Over the map the
pGHERI and subfragments A and B probes are shown. Black box is Exon 1. E = EcoRI, P = PvuII and B = BamHI. Numbers
under the map correspond to the size (in kilobases) of the restriction fragments. b, Southern blot hybridisation of DNA obtained
from four carcinoma tissues (cl-4), and from their normal counterparts (n). White blood cell (wbc) and metastatic lymphonodes
(ml) are from the same patients. c-I and c-2: ER + carcinomas (+ + + and + in respect to the ER status). c-3 and c-4: ER -
carcinomas. MDA (ER -), MCF7 (ER +) and T47D (ER +) are cancer cell lines. On the right side of the figure endometrial
normal (En) and carcinoma (Ec) DNA are included. 10 g of DNA was digested either with BamHI or with BamHI and HpaII
(B/H) and hybridised with 32P-labelled pGHERI probe.
The results of the methylation analysis are summarised in
Table II.
Discussion
Human breast cancer has long been known to contain highly
variable amounts of ER protein which can decrease from
very high to undetectable levels (McGuire, 1978; Kodama et
al., 1985), as can be observed during the progression from
the steroid sensitive to insensitive state (Darbre & King,
1988). In order to investigate the molecular mechanisms
involved in abnormal expression of ER gene we have studied
the structure and the level of methylation of ER DNA in
human breast cancers and in breast cancer cell lines with a
different content of nuclear ER.
No apparent structural alterations of ER DNA were
observed in breast carcinomas, indicating that the abnormal
production of ER is not associated with large chromosomal
rearrangements or deletions. Furthermore, according to data
reported by Henry et al. (1988), no abnormal ER mRNA
bands were detected in ER + cancers; however, differently
from what reported by the same authors, no ER mRNA was
present in the ER - cancers investigated. On the other hand,
differences in ER DNA methylation were found between
normal, carcinomatous and cultured cancer cells in CCGG
sequences located both in the core and in the 5' region of the
ER gene.
Hypomethylation of intragenic CCGG sites (see Figure 2)
was present in 30% of breast carcinomas examined and in all
the breast cancer cells, as shown by the data of Figure 2 and
Table II. Hypomethylation in the breast is different from that
observed in endometrial carcinomas (see Figure 2 and Piva et
al. (1989b)). This observation adds evidence to the fact that
both methylating and demethylating events are strongly
related to the tissue type (Silva & White, 1988). Moreover,
this breast ER DNA hypomethylation, although similar to
the hypomethylation typical of normal endometrium (see
Figure 2) which expresses ER to a high extent (Piva et al.,
1989b), is not constantly associated with an increase of ER
gene expression since the same changes were observed both
in ER + and ER - carcinomas.
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Table II Quantitation of the extent of methylation in the ER DNA
displayed by normal and neoplastic breast tissues and cell lines
Degree of ER DNA methylation
Source of S' region
DNA Inner region Ml M13 M14 ER status
Non-target tissue + + +/- +
Normal breast + +/- - + +
Breast ca +;+/- +/-;- - +;- +
Breast ca - - - ++
Breast ca - - - + + +
Breast ca +;+/- +/-;+ +/-;+ +
Breast ca +/- - - -
Cell lines
Normal endom. +- - - - +++/++
Endom. ca - - - - +
The restriction pattern of DNA from normal and cancer (ca)
breast tissues and cell lines was compared with DNA from white
blood cell (non-target tissue) and normal and neoplastic
endometrium (endom.) which respectively show the highest and
lowest degree of ER DNA methylation. The methylation was
quantitated as follows. Inner region (hybridised with pOR3 probe):
(+) presence of only high molecular DNA fragments; (+/-)
presence of the 3.2kb band; (-) presence of the 1.6kb band. 5'
region (hybridised by the pGHERl probe) = Ml: (+) presence of
the 2.4 kb without the 1.6 kb; (+/-) presence of the 2.4 with the
1.6; (-) presence of the 1.6 only. M13: (+) presence of the 3.2
without the 2.8; (+/-) presence of the 3.2 with the 2.8; (-)
presence of the 2.8 only. M14: (+) absence of the 0.7; (-) presence
of the 0.7 kb band. Different methylation patterns in cancers with
the same ER status are indicated with (+;+/-;-). For examples of
this scoring compare the autoradiographs of Figures 2 and 3. The
ER status is also indicated.
These last findings demonstrate the lack of correlation
between ER expression and methylation of CCGG sites in
the core of the ER gene. Nevertheless, we cannot exclude the
possibility that undermethylation of these sites, always pres-
ent in breast cell lines, may be relevant for assessing tumour
invasiveness or progression.
The CCGG sites of the 5' region of ER gene, excluding
those in the cap site region which are demethylated in all
tissues (Piva et al., 1989a), are partially hypomethylated in
normal breast (Figure 3b) and also in fibroadenomas (data
not presented).
In breast carcinomas a heterogeneous methylation pattern
is found. These sites are markedly hypomethylated in 13 of
the 15 samples which express ER, and hypermethylated in
four of the five ER- samples (Table II). This suggests that
hypomethylation in the 5' end of the gene and not in the core
of the gene is closely related to the gene expression. This
relationship does not exist in breast cancer cell lines because
they are methylated to a low degree, although either positive
or negative to ER antibody. However, methylation was not
as low as that found in the endometrium (Figure 3b). These
observations are again in agreement with the hypothesis of a
tissue constraint in the methylation state which may be lost
in cell cultures.
Alternatively, the differences in methylation observed
between the investigated cancer tissues could reflect
heterogeneity of the cell population, with a high degree of
methylation of ER gene where the stromal cell component is
prevalent. However, the tumour specimens examined for
DNA analysis contained less than 10% of stromal cells (see
Methods section), which is not enough to explain the changes
in methylation observed.
In addition, the differences in ER methylation found in the
breast carcinomas should be related to the different phases of
the menstrual cycle of the patients, as reported for the ER
content (Smith et al., 1988). This does not appear to be the
case because the alterations in methylations were assessed in
relation to the normal counterpart of breast tissue from the
same patient (Figures 2 and 3).
It is also noteworthy that the hypomethylation described
here appears to be specific, since it is not associated with a
general hypomethylation because the same DNA samples are
hypomethylated in 5' and not in the inner regions of the
same gene (c1 of Figures 2 and 3).
In conclusion, the pattern of ER DNA methylation in the
core and particularly in the 5' region of the gene is different
in breast carcinomas from that observed in normal breast
tissue. In breast carcinomas the heterogeneous methylation
pattern of the 5' end of ER DNA is in agreement with the
heterogeneity of the neoplastic cells, particularly with respect
to the ER status. It would be of interest to follow the clinical
course of the patients with different ER methylation patterns
in order to establish whether the ER DNA variations have
prognostic value. In addition to this possible clinical appli-
cation, these results may shed more light on the biological
mechanisms leading to the loss of hormone dependence in
breast cancer.
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